Skip to main navigation

Skip to Content

News
Contact Us
Investors
- Overview
- Events and Presentations
- SEC Filings
- Stock Information
- Corporate Governance
- Investor FAQs
- Email Alerts

Home
About
- About Cullinan
- Leadership
- Partnerships
Research
- R&D
- Programs
- Pipeline
For Patients
- Patient Programs
- Clinical Trials
Working at Cullinan
- Our People
- Careers

News Releases

Year

Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023

May 25, 2023

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 11, 2023

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

April 26, 2023

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

April 20, 2023

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

March 27, 2023

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

March 14, 2023

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

March 9, 2023

Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference

February 27, 2023

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

February 13, 2023

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference

February 2, 2023

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 13

Connect with Us

Follow Us

Site - Social

Site - Footer

Connect With Us
About Us
Terms of Use/Privacy
Accessibility Policy

© COPYRIGHT 2023 Cullinan Oncology, Inc. | ALL RIGHTS RESERVED